BRCA1 Breast Cancer: Carol's Survivor Story

What happened, in summary

In 2018, this patient was diagnosed with triple-negative breast cancer after years of monitoring suspicious areas in the right breast. Genetic testing later showed a BRCA1 mutation, which influenced both breast cancer planning and future ovarian cancer risk management.

For breast cancer, the patient received 16 rounds of chemotherapy: 4 rounds of doxorubicin and cyclophosphamide followed by 12 rounds of paclitaxel. In December 2018, a double mastectomy was performed. Pathology after surgery showed a complete response to chemotherapy, with no living cancer cells remaining in the breast tumor. No additional breast cancer treatment was needed at that time.

The BRCA1 result also led the care team to recommend high-risk gynecologic monitoring and risk-reduction surgery. In 2020, that separate pathway unexpectedly identified an early ovarian cancer, creating a second cancer journey.

Despite facing two primary cancers, the patient remained confident in the medical team and follow-up plan. At the time of the story, there was no evidence of either disease. The breast cancer experience was defined by an intensive chemotherapy course, mastectomy, and a complete pathologic response.